Edinburgh Institute Uses AI to Fast-Track Existing Drug Repurposing for Neurological Conditions
Scientists at the UK Dementia Research Institute in Edinburgh are leveraging artificial intelligence (AI) to accelerate the discovery of treatments for neurological conditions, potentially unlocking therapies hidden within existing drug arsenals.
The Institute's research involves analysing extensive patient data, including voice recordings and eye scans, alongside lab-grown brain cells. The goal is to pinpoint whether already approved drugs, developed for other ailments, could effectively treat conditions such as motor neurone disease (MND), Parkinson's, and dementia.
This innovative strategy employs sophisticated algorithms to detect disease patterns and predict suitable medications. Researchers anticipate this could lead to the identification of effective treatments in "years rather than decades," a substantial reduction in the typical drug development cycle.
Steven Barrett, diagnosed with MND a decade ago, participates in these trials. "MND is a horrible disease, it strips you of who you are," Barrett stated from his home in Alloa, Scotland. He describes the trials as a "bright light" of hope, highlighting the potential for this research to benefit not only himself but countless others.
The Institute is also constructing a comprehensive database of individuals with neurological conditions. Clinicians collect iris scans and voice recordings, using AI to process vast quantities of data. This analysis aims to spot subtle changes that could serve as early indicators of future neurological problems. Furthermore, blood samples from volunteer patients are used to cultivate stem cells into neurones for in-vitro drug testing. Robots and traditional lab equipment, powered by specialist algorithms, test existing drugs on these neurone batches. These machine learning algorithms are specifically trained to identify compounds capable of transforming a neurological disease signature into a healthy one.
Professor Siddarthan Chandran, chief executive of the Institute, noted that there are approximately 1,500 drugs already developed and approved for various conditions. He posits that one or more of these could inadvertently be effective in the brain. "The brain is the most complicated organ in the body, so we've got to contend with the paradox of that complexity," he explained, adding that the combination of AI and new technologies enables research previously considered impossible.
Repurposing existing, approved drugs offers a more direct path to market compared to developing entirely new formulas, which can take over a decade. While earlier 'breakthrough' drugs for Alzheimer's, such as lecanemab and donanemab, have shown limited meaningful difference for patients in comprehensive reviews, Professor Chandran remains confident that neurological research is at a "tipping point of change" in understanding and treatment development.
